Savara Inc (SVRA) @ NASDAQ
Printed Wednesday, 10 June '26 08:53 MST
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Biotechnology Pharmaceuticals, Biotechnology & Life Sciences Common Stock β +0.269
| Date | Name (*Public) | Description | Symbol | Type | Size | Action |
|---|
| Date | Value | Error | Logarithmic | Error | Model (*Public) |
|---|
-$0.13 (2.57%) on Tuesday, 9 June 2026, Marketcap $1.01 B
| Date | Value | Δ | Open | Close | Low | High | Adjusted | Volume | Δ |
|---|
| Name | Version (*Public) | Indicator % | Auto | Description | Symbol | Company Name | Forecasts | Buy / Sell | Action |
|---|
| Opened (Closed) | Expires | Symbol | Company Name | Name (*Public) | Size | Contract Symbol | Open P/L | Close P/L | Total P/L | ROI | DTE | DIT | Delta | Action |
|---|
| Details | Best Trend by Hindsight | Forecast | Profit or Loss | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date (*Public) | Symbol | Strategy | Data | Origin | Slope | Sigma | Cor % | Moves | Sigma | Moves | Gain % | Periods | Action |
| Date | Name (*Public) | Description | Price | Quantity | Total | Cost | Type | Symbol | Action |
|---|
| Date | RSI | Stochastic %D | Stochastic %K | MACD | MACD Divergence | MACD Signal | DMI | CCI | Volatility | Bollinger Upper | Bollinger Mid | Bollinger Lower |
|---|
| Date | Name | Description | Type | Symbol | Company Name | Location |
|---|
| Date UTC | Location | Action | Description | Object | Severity | User | Action |
|---|
